Adam Keeney has been appointed president and chief executive of NodThera, a biotech focused on the discovery and development of NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation.
Dr Keeney is taking the top job at the privately-held UK firm and is establishing a new office in Massachusetts, USA, where he has been based in his previous role with Sanofi Genzyme, part of the French pharma major, Sanofi (Euronext: SAN).
"Attracting a CEO of Adam’s calibre is a testament to the exciting potential of NodThera"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze